Possis Medical
This article was originally published in The Gray Sheet
Executive Summary
Files 510(k) application with FDA for three expanded polytetrafluoroethylene (ePTFE) synthetic vascular grafts, the Minneapolis firm announces Dec. 8. Once approved, the ePTFE grafts will complement Possis' Perma-Seal silicon elastomer dialysis access graft, approved by FDA in September. No independent distributor has been named for either the Perma-Seal or the ePTFE grafts. Possis retained Salomon Smith Barney in January 1998 to explore selling the entire vascular graft business, but the firm says it will not decide the fate of the division until distributors for the current products have been signed